METTL3 promotes microglial inflammation via MEF2C in spinal cord injury

Dongliang Wang,Wei Qian,Duanrong Wu,Ya Wu,Kun Lu,Guoyou Zou
DOI: https://doi.org/10.1007/s00441-023-03855-6
2024-01-06
Cell and Tissue Research
Abstract:Spinal cord injury (SCI) is a significant contributor to disability in contemporary society, resulting in substantial psychological and economic burdens for patients and their family. Microglia-mediated inflammation is an important factor affecting the nerve repair of SCI patients. N 6 -methyladenosine (m 6 A) is a prevalent epigenetic modification in mammals, which shows a strong association with inflammation. However, the mechanism of m 6 A modification regulating microglia-mediated inflammation is still unclear. Here, we observed that METTL3, a m 6 A methylase, was increased in SCI mice and lipopolysaccharide (LPS)-exposed BV2 cells. Knockdown of METTL3 inhibited the increased expression of iNOS and IL-1β induced by LPS in vitro. Subsequently, MEF2C, myocyte-specific enhancer factor 2C, was decreased in SCI mice and LPS-exposed BV2 cells. Knockdown of MEF2C promoted the expression of iNOS and IL-1β. Sequence analysis showed that there were multiple highly confident m 6 A modification sites on the MEF2C mRNA. METTL3 antibody could pull down a higher level of MEF2C mRNA than the IgG in RNA binding protein immunoprecipitation assay. Knockdown of METTL3 promoted MEF2C protein expression and MEF2C mRNA expression, accompanied by a reduced m 6 A modification level on the MEF2C mRNA. Knockdown of MEF2C inhibited the anti-inflammatory effect of METTL3 siRNA. Our results suggest that METTL3 promotes microglia inflammation via regulating MEF2C mRNA m 6 A modification induced by SCI and LPS treatment.
cell biology
What problem does this paper attempt to address?